002932.SHE Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
- Market cap
- CNY 3.33B
- P/E
- -
- P/B
- 0.63x
- ROE
- -0.8%
- Dividend yield
- 7.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002932.SHE undervalued?
Graham numberThe Graham number of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A fundamental analysis
No fundamental analysis for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A yet.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services, as well as nutrition and health products for immune, gut, reproductive, and sleep health management. It also provides information software an…
Full company profileWuhan Easy Diagnosis Biomedicine Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 141M | 165M | 176M | 181M | 959M | 2.83B | 10.5B | 750M | 350M | 265M | 375M |
| Gross Profit | 120M | 134M | 136M | 134M | 749M | 2.12B | 6.54B | 440M | 132M | 95.9M | 150M |
| Operating Income | 67.1M | 75.7M | 68.3M | 41.5M | 562M | 1.70B | 5.08B | 145M | 41.2M | -106M | -48.3M |
| EBITDA | 73.4M | 85.0M | 84.4M | 63.4M | 575M | 1.72B | 5.12B | 217M | 91.0M | -8.96M | -43.7M |
| Net Income | 59.7M | 65.5M | 61.4M | 41.5M | 469M | 1.41B | 4.21B | 74.9M | 74.5M | -16.5M | -45.3M |
| EPS | 0.39 | 0.42 | 0.35 | 0.20 | 2.25 | 6.68 | 18 | 0.33 | 0.33 | -0.07 | -0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 197M | 257M | 617M | 638M | 1.43B | 3.42B | 9.19B | 7.39B | 6.59B | 5.98B | 5.82B |
| Total Liabilities | 22.1M | 13.6M | 24.6M | 22.8M | 312M | 567M | 2.42B | 1.09B | 574M | 325M | 367M |
| Shareholders' Equity | 175M | 241M | 588M | 610M | 1.10B | 2.79B | 6.50B | 6.03B | 5.83B | 5.53B | 5.34B |
| Cash & Short-term Investments | 95.3M | 125M | 268M | 371M | 869M | 1.89B | 4.51B | 1.14B | 558M | 511M | 447M |
| Total Debt | 6.72M | - | 5.39M | - | 142M | 44.4M | 204M | 41.9M | 8.82M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 58.9M | 46.5M | 53.7M | 22.5M | 360M | 1.13B | 4.01B | 392M | -85.0M | -70.1M | - |
| Capital Expenditure | 40.3M | 45.5M | 47.5M | 31.9M | 28.3M | 104M | 313M | 110M | 185M | 90.9M | 38.0M |
| Free Cash Flow | 18.6M | 979K | 6.19M | -9.45M | 331M | 1.02B | 3.70B | 283M | -270M | -161M | -88.0M |
| Ratios | |||||||||||
| ROE | 34.1% | 27.2% | 10.4% | 6.8% | 42.6% | 50.7% | 64.7% | 1.2% | 1.3% | -0.3% | -0.8% |
| ROA | 30.3% | 25.5% | 10.0% | 6.5% | 32.9% | 41.4% | 45.8% | 1.0% | 1.1% | -0.3% | -0.8% |
| Net Profit Margin | 42.3% | 39.7% | 34.8% | 22.9% | 48.9% | 49.9% | 40.0% | 10.0% | 21.3% | -6.2% | -12.1% |
| Debt to Equity | 0.04x | - | 0.01x | - | 0.13x | 0.02x | 0.03x | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A dividends
- Dividend yield
- 7.90%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 12, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 263M | 1.13 | - |
| 2024 | CNY 47.4M | 0.21 | 63.6% |
| 2023 | CNY 582M | 2.57 | 777.4% |
| 2022 | CNY 549M | 2.39 | 13.0% |
| 2021 | CNY 283M | 1.34 | 20.0% |
| 2020 | CNY 6.66M | 0.03 | 1.4% |
| 2019 | CNY 20.0M | 0.10 | 48.1% |
| 2018 | CNY 26.6M | 0.15 | 43.4% |
| 2017 | CNY 26.6M | 0.17 | 40.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.49:1 on Jun 6, 2023.
Who owns Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
- Insiders 48.31%
- Institutions 1.58%
- Public & others 50.12%
- Shares outstanding 233M
- Free float 97.0M
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A company profile
- Company name
- Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
- Ticker
- 002932.SHE
- ISIN
- CNE1000033Q7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 599
- Fiscal year end
- December
- Address
- East Lake New Technology Development Zone, Wuhan, China, 430075
- Phone
- 86 27 6552 3649
- Website
- mdeasydiagnosis.com
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services, as well as nutrition and health products for immune, gut, reproductive, and sleep health management. It also provides information software and supporting hardware products. In addition, the company offers blood gas and chemistry analyzers, fluorescence immunoassay analyzers, molecular diagnosis kit, coagulation analysis machine, and automated glycohemoglobin detection machine. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A management
4- Ms. Chen Li LiChairman & GM · born 1974
- Ms. Wang YingVice Chairman & Deputy GM · born 1974
- Mr. Rui WangDeputy GM, CFO & Board Secretary · born 1978
- Chaohui LiAccounting Supervisor